- Tương quan Spearman (kí hiệu bằng chữ R) còn được gọi lă tương quan số hạng (Rank correlation): tương quan giữa biến định tính vă biến định
Chương 4 BĂN LUẬN
TIẾNG VIỆT
1. Trần Hữu Dăng (2002), “Nghiín cứu tăng huyết âp ở người bĩo phì”, Kỷ
yếu toăn văn câc đề tăi khoa học Đại hội Tim mạch học quốc gia Việt Nam lần thứ IX, 90-93.
2. Ngô Như Hoă (1981), “Thống kí trong nghiín cứu y học”, Điều tra một số
hằng số sinh học, sử dụng một hằng số sinh học trong chẩn đoân bệnh, tập 1, NXB Y học, 129-153.
3. Nguyễn Phú Khâng (1996), “Suy tim mạn tính”, Lđm săng tim mạch, NXB Y học, 161-165.
4. Huỳnh Văn Minh (2006), Hướng dẫn số 1 về chẩn đoân, điều trị , dự phòng
tăng huyết âp của phđn hội tăng huyết âp Việt Nam (VSH).
5. Nguyễn Xuđn Phâch (2000), ”Ma trận quyết định”, Thống kí y học, NXB Y học, 50-51.
6. Nguyễn Xuđn Phâch (1995), ”Tương quan”, Thống kí y học, Nhă xuất bản Y học, 109-129.
7. Nguyễn Mạnh Phan (2006), Thời sự chẩn đoân vă điều trị bệnh tim mạch
tập (1) dịch từ Current Diagnostic & Treatment in Cardiology của Michael H. Crawford.
8. Phạm Nguyễn Vinh (2002), Bệnh học tim mạch, Tập 1, Nhă xuất bản Y học, 205-214.
9. Phạm Nguyễn Vinh vă cs. (2006), Khuyến câo về chẩn đoân vă điều trị suy
tim.
10. Phạm Nguyễn Vinh (2003), “ Chẩn đoân vă điều trị suy tim mạn tại Việt Nam”, Kỷ yếu công trình nghiín cứu khoa học Hội nghị Tim mạch học
et al. (2002), “Rapid Measurement of B-Type Natriuretic peptide in the Emergency Diagnosis of Heart Failure”, NEJM, 347, 161-167.
12. American Heart Association (2005), “Heart Disease and Stroke statistics, Update Dallas, Texas”.
13. Andrzej Gackowski, Richard Isnard, Jean-Louis Golmard, FranìoisePousset, Alain Carayon, Gilles Montalescot, Jean-Sebastien Hulot, Pousset, Alain Carayon, Gilles Montalescot, Jean-Sebastien Hulot, Daniel Thomas, Wieslawa Piwowarska and Michel Komajda (2004), “Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure“,
European Heart Journal, Vol. 25, No. 20.
14. Antoni Bayĩs-Genís, MD (2005),”NT-ProBNP Reduction Percentage
During Admission for Acutely Decompensated Heart Failure Predicts Long-Term Cardiovascular Mortality”, Journal of Cardiac Failure Vol. 11, No. 5
15. Brauwald E. (1998), “Heart failure”, Heart disease, 3rd edition, 1367- 1389.
16. Brauwald E., Fauci A.S. (1998), “Heart failure”, Harrison’s Principles of
Internal medicin, McGraw Hill, 14th edition, Vol 1, 1287-1294.
17. Burger A, Burger M.(2001),”BNP in decompensated heart failure diagnostic, prognosis and therapeutic potential”, Curr Invest Drugs, 2: 929-935.
18. Campbell DJ, Mitchelhill KI, Schlicht SM et al. (2000), “Plasma amino- terminal pro brain natriuretic peptide: anovel approach to the diagnosis of cardiac dysfuntion”, Jcard Fail, 6:130-139.
20. Christian Hall (2004), “Essential biochemistry and physiology of (NT- Pro)BNP”, The European Heart Journal of Heart Failure, 6:257-260. 21. ClerioA. (2002), “The circulating levels of cardiac natriuretic hormones in
healthy adults: effect of age and sex”, Clin Chem Lab Med , 40:371-7. 22. Eric Stantona, Mark Hansenb, Hairinda C. (2005), “A direct comparison
of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin”, The European
Journal of Heart Failure, 7: 557- 565.
23. Felker GM vă cs., (2003), “Definition of acute decompensated heart failure”, Am Heart J, 145: 18-25.
24. Frank Schoonjans (2004), MedCal 7.3.0.1, www.medcalc.be
25. Franklin H. Epstein, M.D.(1998).,”Natriuretic Peptides ”, Mechanisms of
disease, www.nejm.org.
26. Franz Hartmann, Milton Packer, Andrew J.S. Coats et al. (2003), “NT- ProBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-ProBNP substudy”, The European
Journal of Heart Failure, 6: 343-350.
27. Giannesi D, Andreassi MG, Del Ry S, et al. (2001), “Possibility of age regulation of the natriuretic peptide C-receptor in human plateles”,
Endocrinol Invest, 24:8-16.
28. Hama N, Itoh H, Shirakami G, et al. (1995), “Rapid ventricular induction of brain natriureticpeptide gene expression in experimental acute
myocardial infarction”, Circulation, 92, 1558-1564.
29. Hanley JA, McNeill BJ (1982),” The meaning and use of the area under a receiver operator characteristic (ROC) curve”, Radiology, 143: 29-36.
ANP/BNP production in cardiocyte culture”, J Cardiovasc Phamacol
31(supp1), S357-359.
31. Heger J.W., Niemann J.T., Roth R.F. (1998), “Congestive Heart Failure”,
Cardiology, William & Wilkin 4th edition, 217-236.
32. Henriksen JH, Gotze JP, Fuglsang S, et al. (2003), “Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patient with cirrhosis: relation to cardiovascular dysfunction and severity of disease”, Gut, 52: 1511-1517.
33. Hobbs FDR et al. (2002), ”Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations”, BMJ, 324-1498.
34. Hunt PJ, Richard AM, Nicholls MG et al. (1997), “Immunoreactive amiono-terminal pro-brain natriuretic peptide (NT-ProBNP) a new marker of cardiac impairment”, Clin Endocrinol (Oxf), 47:287-296. 35. Hunter JJ, Chien KR. (1999), “Signaling pathways for cardiac
hypertrophy and failure”, N Engl J Med ,341: 1276-83.
36. Januzzi Jl Jr, Camargo CA, Anwaruddin S, et al. (2005), “The N-terminal ProBNP Investigation of dysnea in the Emergency Department (PRIDE) study”, Am J Cardiol, 95:948-954.
37. Kazanegra R, Cheng V, Garcia A, et al. (2001), “A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study”, J Card Fail , 7: 21-29.
38. Kirk V., Bay M, Parner J. et al. (2004),”N-Terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs.
Failure 6: 335-341.
39. Lemos JA, Morrow DA, (2002),”Brain natriuretic peptide measurement in acute coronary syndromes; ready for clinical application?”, Circulation, 106: 2868-2870.
40. Levin ER, Gardner DG, Samson WK (1998), ”Natriuretic peptides”, N
Engl J Med, 339: 321-328.
41. Maeda K, Tsutamoto T, Wada A, et al. (1998), “Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction”, Am
Heart J, 135: 825-832.
42. Magga J, Marttila M, Mantymaa P et al.(1994), “ Brain natriuretic peptide in plasma, atria and ventricules of vasopressin and phenylephrine- infused conscious rats”, Endocrinology, 134: 2505-2515.
43. Mair J, Frieddl W, Thomas S, Puschendorf (1999), ”B-type Natriuretic peptides in assessment of left-ventricular dysfunction, Scand J Clin Lab
Invest, 59 (suppl 230): 132-42.
44. Maisel AS, Krishnaswamy P, Nowak RM, et al. (2002), “Breathing Not Properly Multinational Study Investigators. Rapid measurement of B- type natriuretic peptide in the emergency diagnosis of heartfailure”, N
Engl J Med, 347: 161-167.
45. Marc Vanderheyden, Jozef Bartunek, Marc Goethals (2004), “Brain and other natriuretic peptides: molecular aspect”, The European Heart
Journal of Heart Failure, 6: 261-268.
46. Markku S. Nieminen (2005), “Guidelines on the diagnosis and treatment of acute heart failure-fulltext”, European Heart Jounal, ESC guidelines.
ambulatory patients with heart failure”, Clin Chem Lab Med, 40:761-763. 48. McCullough PA, Sandberg KR (2003), ”Sorting out the evidence on
natriureticpeptides”, Rev Cardio Vasc Med, 4:13-19.
49. McDonagh T.A., Holmer S., Raymond I et al. (2004),“NT-ProBNP and the diagnosis of heart failure: a pool analysis of three European epidemiological studies”, The European Journal of Heart Failure, 6: 269-273.
50. McKee PA, Castelli WP, McNamara PM, Kannel WB (1971), “The nature history of congestive heart failure: the Framingham study”, N Engl J
Med, 285(26): 1441-1446.
51. Mueller C, Scholer A, Laule-Kilian K et al. (2004), “Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea”,
N. Engl. J. Med, 350: 647-654.
52. Olav Wendelboe, Nielsen, Vibeke Kirk, Morten Bay et al. (2004),” Value of N-terminal pro brain natriuretic peptide in the elderly: data from the prospective Copenhagen Hospital Heart Failure study (CHHF)”, The
European Journal of Heart Failure, 6: 275-279.
53. Olsen MH, Wachtell K, Tuxen C, et al., (2003), ”N-terminal pro Brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy, a LIFE study”, J
Hypertension, In press.
54. Paulo Bettencourt, (2004), “NT-ProBNP and BNP: biomarkers for heart failure management”, The European Journal of Heart Failure, 6: 359- 363.
Hypertension, 36:355-359.
56. Pert Jarolim (2006), “Serum biomarkers for heart failure”,
Cardiovascular Pathology 15, 144-149.
57. Pfister R., Scholz M., Wielckens K. et al. (2004), “Use of NT-ProBNP in routing testing and comparison to BNP”, The European Heart Journal of
Heart Failure, 6: 289-293.
58. Pfister R, Scholz, Wielckens K, et al. (2002), ”The value of natriuretic peptides NT-ProBNP and BNP for the assessment of left ventricular volume and function. A prospective study of 150 patients”, Dtsch Med
Wochenschr, 127: 2605-2609.
59. Philbin EF, DiSalvo TG. (1999), “Prediction of hospital readmission for
heart failure: development of a simple risk score based on administrative data”, J Am Coll Cardiol, 33: 1560-1566.
60. Porth C.M. (1998), Pathophysiology, 3rd edition, J.B Lippincott, 378-387 and 483-509.
61. Raizada V, Thakore K, Luo W et al. (2001), “Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension”, Mol Cell Biochem, 216: 137-40.
62. Raymond I, Groenning BA, Hildebrandt PR et al. (2003), “The influence of age, sex and other variables on the plasma level of N-terminal Pro brain natriuretic peptide in a large sample of the general population”,
Heart, 89: 745-751.
63. Remme W. J. and Swedberg K.(2001), “Guidelines for the diagnosis and treatment of chronic heart failure”, European Society of Cardiology.
predictors of left ventricular function and prognosis after myocardia infarction”, Circulation, 97: 1921-1929.
65. Robert Berkowitz (2004), ”B-Type Natriuretic Peptide and the Diagnosis of Acute Heart Failure”, Optimizing Heart Failure Management, Vol. 5, 3-16.
66. Roche Diagnosis Corporation (2003), “ProBNP (ProBrain Natriuretic Peptide)”, Elecsys System 1010/2010/Modular analytics E170.
67. Saeed A. Jortani,1 Sumanth D. Prabhu and Roland Valdes, Jr. (2004), “Strategies for Developing Biomarkers of Heart Failure”, Clinical
Chemistry, 50:265-278.
68. Sayama H, Nakamura Y, Saito N et al. (1999), “Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal?”, Coron Atery Dis, 10:537-540.
69. Schulz H, Langvik TA, Lund Sagen E, et al. (2001), ”Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma”, Scand J
Clin Lab Invest, 61: 33-42.
70. Shimizu H, Masuta K, Asada H, et al. (2003), ”Characterization of molecular forms of probrain natriuretic peptide in human plasma”, Clin
Chim Acta, 334: 233-239.
71. Talwar S, Squire IB, Davies JE et al. (1999), “Plasma N-terminal ProBNP natriuretic peptide and the ECG in assessment of left ventricular systolic dysfuntion in a high risk population”, 20: 1736-1744.
72. Tomas Jernberg, Stefan James, Berti Lindahl et al (2004), “NT-ProBNP in unstable coronay artery disease-experiences from the FAST, GUSTO IV
73. Tsuruda T, Boeringter G, Huntley BK and al. (2002), ”Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases”, Circ Res, 91: 1127-1134.
74. Wang TJ, Larson Mg, Levy D et al. (2002), “Impact of age and sex on plasma natriuretic peptide levels in healthy adults”, Am J Cardiol, 90: 254-358.
75. Wieczoerck SJ, Wu AHB, Christension R et al. (2002),” Multi-center clinical evaluation of the Triage B-type natriuretic peptide (BNP) assay for the diagnosis of heart failure”, Am Heart J , 144: 834-839.
76. WHO/ISH writing group (2003), “World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension”, www.who.int
77. WHO (2000), “The international classification of adult underweight, overweight and obesity according to BMI”, www.who.int
78. WHO - Western Pacific Region, IASO( International Association for the Study of Obesity) (2000),”The Asian-Pacific respective: Redefining obesity and its treatment”, www.who.int
79. Wright SP, Doughty RN, Pearl A et al. (2003), “ Plasma amino-terminal pro- brain natriuretic peptide and accuracy of heart failure diagnosis in primary care: a randomized controlled trial”, J Am Coll Cardiol, 42: 1793-1800.
80. Yasue H., Yoshimura M., Sumida.(1997),”Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure”,
assay”, Clin Chim Acta, 338: 107-115.
82. Yoshihiko Seino, Akio Ogawa, Teruyo Yamashita et al. (2003), ”Application of NT-ProBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure”,
The European Journal of Heart Failure, 6: 295-300.
83. Zhang Xiang-yang, Zhu Ji-hong (2004), “Clinical significance of N- terminal pro-brain natriuretic peptide”, Chinese Medical Journal, 117(11):1716-1722.